ProCE Banner Activity

My Thoughts on Key Issues With PARP Inhibitors for Prostate Cancer

Clinical Thought
Heather H. Cheng, MD, PhD, answers questions on key issues raised by the audience that attended a live CCO symposium on the current and expanding role of PARP inhibitors in the care of patients with prostate cancer.

Released: April 26, 2022

Expiration: April 25, 2023

No longer available for credit.

Share

Faculty

Heather H. Cheng

Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Hematology and Oncology)
University of Washington
Division of Clinical Research
Fred Hutchinson Cancer Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Hematology and Oncology)
University of Washington
Division of Clinical Research
Fred Hutchinson Cancer Center
Seattle, Washington

Heather H. Cheng, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca and funds for research support from Astellas, Clovis, Color Genomics, Janssen, Medivation, Phosplatin, and Sanofi.